Predictor for an Additional Benefit of Inhaled Corticosteroid in Patients Treated With Tiotropium for COPD

PHASE4CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

August 31, 2010

Study Completion Date

October 31, 2010

Conditions
COPD
Interventions
DRUG

Budesonide

After 4 weeks of inhalative therapy with tiotropium (all patients), patient get randomized to receive either inhalative budesonide (1600ug per day or placebo

Trial Locations (1)

4031

University Hospital Basel, Basel

All Listed Sponsors
lead

Cantonal Hosptal, Baselland

OTHER

NCT00860938 - Predictor for an Additional Benefit of Inhaled Corticosteroid in Patients Treated With Tiotropium for COPD | Biotech Hunter | Biotech Hunter